Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn’s Disease With a Loss of Response

BACKGROUND/AIMS: In patients receiving ustekinumab (UST) for treatment of Crohn’s disease, there is no proven strategy to enhance or re-capture response. We assessed the utility of UST intravenous (IV) reinduction (~6 mg/kg) to achieve clinical, biochemical and endoscopic response or remission, in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Heron, Valerie, Li Fraine, Steven, Panaccione, Nicola, Restellini, Sophie, Germain, Pascale, Candido, Kristina, Bernstein, Charles N, Bessissow, Talat, Bitton, Alain, Chauhan, Usha K, Lakatos, Peter L, Marshall, John K, Michetti, Pierre, Seow, Cynthia H, Rosenfeld, Greg, Panaccione, Remo, Afif, Waqqas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527659/
https://www.ncbi.nlm.nih.gov/pubmed/36196277
http://dx.doi.org/10.1093/jcag/gwac017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527659/
https://www.ncbi.nlm.nih.gov/pubmed/36196277
http://dx.doi.org/10.1093/jcag/gwac017

Ejemplares similares